Glucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) is an intestinally derived insulinotropic hormone currently under investigation for use as a novel therapeutic agent in the treatment of type 2 diabetes. One of several important effects of GLP‐1 is on nutrient‐induced pancreatic hormone release and is mediated by binding to a specific G‐protein coupled receptor resulting in the activation of adenylate cyclase and an increase in cAMP generation. In the β‐cell, cAMP binds and modulates activities of both protein kinase A and cAMP‐regulated guanine nucleotide exchange factor II, thereby enhancing glucose‐dependent insulin secretion. The stimulatory action of GLP‐1 on insulin secretion involves interaction with a plethora of signal transduction processes including ion channel activity, intracellular Ca 2+ handling and exocytosis of the insulin‐containing granules. In this review we focus principally on recent advances in our understanding on the cellular mechanisms proposed to underlie GLP‐1's insulinotropic effect and attempt to incorporate this knowledge into a working model for the control of insulin secretion. Lastly, this review discusses the applicability of GLP‐1 as a therapeutic agent for the treatment of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“1993) and inhibits food intake (Flint et al. 1998).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Insulin granule dynamics in pancreatic beta cells
Rorsman, P., & Renstr�m, E. (2003) · Diabetologia · doi:10.1007/s00125-003-1153-1 · Cited by 844
Self-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
cAMP-GEFII is a direct target of cAMP in regulated exocytosis
Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · cited 5×
“Recent data suggest that the stimulatory effect of cAMP on insulin secretion is mediated via two distinct pathways: PKA-dependent and -independent (Renström et al. 1997; Ozaki et al. 2000; Eliasson et al. 2003; Kang & Holz 2003).”
BackgroundMethodInfluential
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Meloni, A. R., DeYoung, M. B., Lowe, C., & Parkes, D. G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01663.x · Cited by 407
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Metadata
- Authors
- Gromada, J., Brock, B., Schmitz, O., & Rorsman, P.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2004-11-29
- Volume
- 95
- Issue
- 6
- Pages
- 252-262
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W2077118054
- Cited by
- 105
- References
- 24
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential. https://app.cochat.ai/papers/10.1111/j.1742-7843.2004.t01-1-pto950502.x
- The paper
- Gromada, J., Brock, B., Schmitz, O., & Rorsman, P. (2004). Glucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/j.1742-7843.2004.t01-1-pto950502.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.